SEC Form 4 · accession 0001562180-17-001360
ARRAY BIOPHARMA INC · ARRY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Charles M Baum
Director
Period of report
Mar 28, 2017
Accepted (ET)
Mar 30, 2017 · 5:23 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001100412
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 28, 2017 | M | 25,000 | $3.87 | A | 30,000 | D | |
| Common StockF1 | Mar 28, 2017 | S | 25,000 | $9.27 | D | 5,000 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy) | $3.87 | Mar 28, 2017 | M | 25,000 | D | Oct 30, 2015 | Oct 30, 2024 | Common Stock | 25,000 | 0 | D |
Explanation of responses
- F1The price reported for these shares is the weighted average sale price. Details of actual prices for shares sold are available from the Issuer upon request.